{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:13:11Z","timestamp":1772165591949,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"China National Key R&D Project","award":["2022YFC2503504"],"award-info":[{"award-number":["2022YFC2503504"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-024-04399-5","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T05:55:20Z","timestamp":1734587720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduced-dose of bivalirudin (without the post-procedure infusion) in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention"],"prefix":"10.1186","volume":"24","author":[{"given":"Qian","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tienan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaozeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"4399_CR1","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289\u2013367. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575.","journal-title":"Eur Heart J"},{"key":"4399_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehx393.","journal-title":"Eur Heart J"},{"key":"4399_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s11095-019-2676-6","volume":"36","author":"S Han","year":"2019","unstructured":"Han S, Kim YH, Choi HY, Kim MJ, Kim WJ, Park H, et al. Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of CTB-001, a recently developed generic of Bivalirudin. Pharm Res. 2019;36:146. https:\/\/doi.org\/10.1007\/s11095-019-2676-6.","journal-title":"Pharm Res"},{"key":"4399_CR4","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1161\/cir.0000000000001039","volume":"145","author":"JS Lawton","year":"2022","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC\/AHA\/SCAI Guideline for Coronary Artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines. Circulation. 2022;145:e4\u201317. https:\/\/doi.org\/10.1161\/cir.0000000000001039.","journal-title":"Circulation"},{"key":"4399_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-0040-1718729","volume":"121","author":"HK Kim","year":"2021","unstructured":"Kim HK, Tantry US, Smith SC Jr., Jeong MH, Park SJ, Kim MH, et al. The East Asian Paradox: an updated position Statement on the challenges to the current antithrombotic strategy in patients with Cardiovascular Disease. Thromb Haemost. 2021;121:422\u201332. https:\/\/doi.org\/10.1055\/s-0040-1718729.","journal-title":"Thromb Haemost"},{"issue":"2","key":"4399_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/CD9.0000000000000025","volume":"1","author":"DY Hu","year":"2021","unstructured":"Hu DY, Han YL, Ning G, Ma CS. Chinese Guideline on the primary Prevention of Cardiovascular diseases. Cardiol Discovery. 2021;1(2):70\u2013104. https:\/\/doi.org\/10.1097\/CD9.0000000000000025.","journal-title":"Cardiol Discovery"},{"issue":"5","key":"4399_CR7","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cpt.2526","volume":"112","author":"CR Lee","year":"2022","unstructured":"Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine M, Stein CM, et al. Clinical pharmacogenetics implementation Consortium Guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022;112(5):959\u201367. https:\/\/doi.org\/10.1002\/cpt.2526.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"4399_CR8","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41598-017-18134-y","volume":"8","author":"HJ Joo","year":"2018","unstructured":"Joo HJ, Ahn SG, Park JH, Park JY, Hong SJ, Kim SY, et al. Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: a prospective multicentre registry study. Sci Rep. 2018;8(1):1229. https:\/\/doi.org\/10.1038\/s41598-017-18134-y.","journal-title":"Sci Rep"},{"issue":"1","key":"4399_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ahj.2012.10.013","volume":"165","author":"DW Park","year":"2013","unstructured":"Park DW, Ahn JM, Song HG, Lee JY, Kim WJ, Kang SJ, et al. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention. Am Heart J. 2013;165(1):34\u2013e421. https:\/\/doi.org\/10.1016\/j.ahj.2012.10.013.","journal-title":"Am Heart J"},{"issue":"4","key":"4399_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.gheart.2014.08.001","volume":"9","author":"GN Levine","year":"2014","unstructured":"Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, et al. World heart federation expert consensus statement on antiplatelet therapy in east Asian patients with ACS or undergoing PCI. Glob Heart. 2014;9(4):457\u201367. https:\/\/doi.org\/10.1016\/j.gheart.2014.08.001.","journal-title":"Glob Heart"},{"issue":"2","key":"4399_CR11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","volume":"153","author":"JKY Hooi","year":"2017","unstructured":"Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and Meta-analysis. Gastroenterology. 2017;153(2):420\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2017.04.022.","journal-title":"Gastroenterology"},{"issue":"1","key":"4399_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/1747493016647736","volume":"13","author":"JS Kim","year":"2018","unstructured":"Kim JS, Kim YJ, Ahn SH, Kim BJ. Location of cerebral atherosclerosis: why is there a difference between East and West? Int J Stroke. 2018;13(1):35\u201346. https:\/\/doi.org\/10.1177\/1747493016647736.","journal-title":"Int J Stroke"},{"key":"4399_CR13","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ccd.28858","volume":"97","author":"SJ Brener","year":"2021","unstructured":"Brener SJ, Lembo NJ, Kandzari DE, Sabat\u00e9 M, Gershlick AH, Banning AP, et al. Antithrombotic regimens for percutaneous coronary intervention of the left main coronary artery: the EXCEL trial. Catheter Cardiovasc Interv. 2021;97:766\u201373. https:\/\/doi.org\/10.1002\/ccd.28858.","journal-title":"Catheter Cardiovasc Interv"},{"key":"4399_CR14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1177\/2048872618805663","volume":"8","author":"D Erlinge","year":"2019","unstructured":"Erlinge D, Koul S, Omerovic E, Fr\u00f6bert O, Linder R, Danielewicz M, et al. Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2019;8:492\u2013501. https:\/\/doi.org\/10.1177\/2048872618805663.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"4399_CR15","doi-asserted-by":"publisher","first-page":"e008671","DOI":"10.1161\/circinterventions.119.008671","volume":"13","author":"A Wester","year":"2020","unstructured":"Wester A, Attar R, Mohammad MA, Isma N, James S, Omerovic E, et al. Bivalirudin Versus Heparin Monotherapy in Elderly patients with myocardial infarction: a Prespecified Subgroup Analysis of the VALIDATE-SWEDEHEART trial. Circ Cardiovasc Interv. 2020;13:e008671. https:\/\/doi.org\/10.1161\/circinterventions.119.008671.","journal-title":"Circ Cardiovasc Interv"},{"key":"4399_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/eurheartj\/ehn586","volume":"30","author":"R Iijima","year":"2009","unstructured":"Iijima R, Ndrepepa G, Mehilli J, Byrne RA, Schulz S, Neumann FJ, et al. Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. Eur Heart J. 2009;30:290\u20136. https:\/\/doi.org\/10.1093\/eurheartj\/ehn586.","journal-title":"Eur Heart J"},{"key":"4399_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/ehjcvp\/pvz051","volume":"6","author":"CC Chang","year":"2020","unstructured":"Chang CC, Chichareon P, Modolo R, Takahashi K, Kogame N, Tomaniak M, et al. Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. Eur Heart J Cardiovasc Pharmacother. 2020;6:22\u201330. https:\/\/doi.org\/10.1093\/ehjcvp\/pvz051.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"4399_CR18","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1507854","volume":"373","author":"M Valgimigli","year":"2015","unstructured":"Valgimigli M, Frigoli E, Leonardi S, Rothenb\u00fchler M, Gagnor A, Calabr\u00f2 P, et al. Bivalirudin or Unfractionated Heparin in Acute Coronary syndromes. N Engl J Med. 2015;373:997\u20131009. https:\/\/doi.org\/10.1056\/NEJMoa1507854.","journal-title":"N Engl J Med"},{"key":"4399_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/cm9.0000000000001757","volume":"135","author":"P Wang","year":"2021","unstructured":"Wang P, Zhao X, Yuan Q, Yu X, Yang L, Wang X. Efficacy and safety of bivalirudin without post-procedure infusion in patients with coronary heart disease during elective percutaneous coronary intervention: a real-world study. Chin Med J (Engl). 2021;135:116\u20138. https:\/\/doi.org\/10.1097\/cm9.0000000000001757.","journal-title":"Chin Med J (Engl)"},{"key":"4399_CR20","doi-asserted-by":"publisher","first-page":"864048","DOI":"10.3389\/fcvm.2022.864048","volume":"9","author":"Q Hu","year":"2022","unstructured":"Hu Q, Han YL, Zhou TN, Wang XZ, Zhang QY. Efficacy and safety of the reduced bivalirudin in patients undergoing coronary angiography or percutaneous coronary intervention stratified by renal function (REDUCE BOLUS): a Single-Blind, stratified Randomized, non-inferiority trial. Front Cardiovasc Med. 2022;9:864048. https:\/\/doi.org\/10.3389\/fcvm.2022.864048.","journal-title":"Front Cardiovasc Med"},{"key":"4399_CR21","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC\/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines. J Am Coll Cardiol. 2016;68:1082\u2013115. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.513.","journal-title":"J Am Coll Cardiol"},{"key":"4399_CR22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3917\/jib.151.0124","volume":"15","author":"WMAG Assembly","year":"2004","unstructured":"Assembly WMAG. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique. 2004;15:124\u20139.","journal-title":"J Int Bioethique"},{"key":"4399_CR23","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/circulationaha.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344\u201351. https:\/\/doi.org\/10.1161\/circulationaha.106.685313.","journal-title":"Circulation"},{"key":"4399_CR24","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/circulationaha.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736\u201347. https:\/\/doi.org\/10.1161\/circulationaha.110.009449.","journal-title":"Circulation"},{"key":"4399_CR25","doi-asserted-by":"publisher","unstructured":"Reed MD, Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy. 2002;22:105s-111s. https:\/\/doi.org\/10.1592\/phco.22.10.105s.33616","DOI":"10.1592\/phco.22.10.105s.33616"},{"key":"4399_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.04.003","volume":"152","author":"TA Mavrakanas","year":"2015","unstructured":"Mavrakanas TA, Chatzizisis YS. Bivalirudin in stable angina and acute coronary syndromes. Pharmacol Ther. 2015;152:1\u201310. https:\/\/doi.org\/10.1016\/j.pharmthera.2015.04.003.","journal-title":"Pharmacol Ther"},{"issue":"38","key":"4399_CR27","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1714\/4191.41785","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720\u2013826. https:\/\/doi.org\/10.1714\/4191.41785.","journal-title":"Eur Heart J"},{"issue":"2","key":"4399_CR28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4037\/ccn2005.25.2.88","volume":"25","author":"A Galli","year":"2005","unstructured":"Galli A, Palatnik A. What is the proper activated clotting time (ACT) at which to remove a femoral sheath after PCI? What are the best protocols for sheath removal? Crit Care Nurse. 2005;25(2):88\u201392.","journal-title":"Crit Care Nurse"},{"key":"4399_CR29","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jcin.2014.11.002","volume":"8","author":"P Clemmensen","year":"2015","unstructured":"Clemmensen P, Wiberg S, Van\u2019t Hof A, Deliargyris EN, Coste P, Ten Berg J, et al. Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European ambulance Acute Coronary Syndrome Angiography). JACC Cardiovasc Interv. 2015;8:214\u201320. https:\/\/doi.org\/10.1016\/j.jcin.2014.11.002.","journal-title":"JACC Cardiovasc Interv"},{"key":"4399_CR30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/978-1-0716-3175-1_24","volume":"2663","author":"S Davidson","year":"2023","unstructured":"Davidson S. Assays to Monitor Bivalirudin. Methods Mol Biol. 2023;2663:369\u201380. https:\/\/doi.org\/10.1007\/978-1-0716-3175-1_24.","journal-title":"Methods Mol Biol"},{"key":"4399_CR31","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacc.2018.12.023","volume":"73","author":"G Gargiulo","year":"2019","unstructured":"Gargiulo G, Carrara G, Frigoli E, Leonardi S, Vranckx P, Campo G, et al. Post-procedural Bivalirudin infusion at full or low regimen in patients with Acute Coronary Syndrome. J Am Coll Cardiol. 2019;73:758\u201374. https:\/\/doi.org\/10.1016\/j.jacc.2018.12.023.","journal-title":"J Am Coll Cardiol"},{"key":"4399_CR32","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/s0140-6736(09)61484-7","volume":"374","author":"R Mehran","year":"2009","unstructured":"Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374:1149\u201359. https:\/\/doi.org\/10.1016\/s0140-6736(09)61484-7.","journal-title":"Lancet"},{"key":"4399_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.carrev.2014.08.010","volume":"15","author":"MJ Lipinski","year":"2014","unstructured":"Lipinski MJ, Lhermusier T, Escarcega RO, Baker NC, Magalh\u00e3es MA, Torguson R, et al. Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials. Cardiovasc Revasc Med. 2014;15:315\u201322. https:\/\/doi.org\/10.1016\/j.carrev.2014.08.010.","journal-title":"Cardiovasc Revasc Med"},{"key":"4399_CR34","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1001\/jama.2015.2323","volume":"313","author":"Y Han","year":"2015","unstructured":"Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA. 2015;313:1336\u201346. https:\/\/doi.org\/10.1001\/jama.2015.2323.","journal-title":"JAMA"},{"issue":"10366","key":"4399_CR35","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","volume":"400","author":"Y Li","year":"2022","unstructured":"Li Y, Liang Z, Qin L, Wang M, Wang X, Zhang H, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. Lancet. 2022;400(10366):1847\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(22)01999-7.","journal-title":"Lancet"},{"key":"4399_CR36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/ccd.28065","volume":"94","author":"R Shah","year":"2019","unstructured":"Shah R, Latham SB, Porta JM, Naz A, Matin K, Rao SV. Bivalirudin with a post-procedure infusion versus heparin monotherapy for the prevention of stent thrombosis. Catheter Cardiovasc Interv. 2019;94:210\u20135. https:\/\/doi.org\/10.1002\/ccd.28065.","journal-title":"Catheter Cardiovasc Interv"},{"key":"4399_CR37","doi-asserted-by":"publisher","unstructured":"Fahrni G, Wolfrum M, De Maria GL, Banning AP, Benedetto U, Kharbanda RK. Prolonged high-dose bivalirudin infusion reduces major bleeding without increasing stent thrombosis in patients undergoing primary percutaneous coronary intervention: Novel insights from an updated Meta-analysis. J Am Heart Assoc. 2016;5. https:\/\/doi.org\/10.1161\/jaha.116.003515.","DOI":"10.1161\/jaha.116.003515"},{"key":"4399_CR38","doi-asserted-by":"publisher","unstructured":"Stefano B, Luigi G, Francesco DM. Della Mora., Leonardo, Periprocedural antithrombotic strategies in acute coronary syndromes undergoing percutaneous coronary intervention: have we discarded bivalirudin too soon? Cardiovasc Revasc Med, 57(0), 0. https:\/\/doi.org\/10.1016\/j.carrev.2023.06.014","DOI":"10.1016\/j.carrev.2023.06.014"},{"issue":"16","key":"4399_CR39","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1161\/CIRCULATIONAHA.123.063946","volume":"148","author":"B Bikdeli","year":"2023","unstructured":"Bikdeli B, Erlinge D, Valgimigli M, Kastrati A, Han Y, Steg PG, et al. Bivalirudin Versus Heparin during PCI in NSTEMI: individual Patient Data Meta-Analysis of large randomized trials. Circulation. 2023;148(16):1207\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.063946.","journal-title":"Circulation"},{"issue":"7","key":"4399_CR40","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/ehjcvp\/pvad029","volume":"9","author":"M Galli","year":"2023","unstructured":"Galli M, Gargiulo G, Benenati S, Mehran R, Angiolillo DJ. Bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome. Eur Heart J Cardiovasc Pharmacother. 2023;9(7):666\u20138. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad029.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"4399_CR41","doi-asserted-by":"publisher","first-page":"6667","DOI":"10.1038\/s41598-023-34008-y","volume":"13","author":"Z Wu","year":"2023","unstructured":"Wu Z, Meng P, Guo Y, You W, Wu X, Ye F. Prolonged infusion of bivalirudin after elective percutaneous coronary intervention protects against procedural myocardial injury (a COBER study)-a randomized trial. Sci Rep. 2023;13(1):6667. https:\/\/doi.org\/10.1038\/s41598-023-34008-y.","journal-title":"Sci Rep"},{"key":"4399_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","volume":"19","author":"D Capodanno","year":"2022","unstructured":"Capodanno D, Bhatt DL, Gibson CM, James S, Kimura T, Mehran R, et al. Bleeding avoidance strategies in percutaneous coronary intervention. Nat Rev Cardiol. 2022;19:117\u201332. https:\/\/doi.org\/10.1038\/s41569-021-00598-1.","journal-title":"Nat Rev Cardiol"},{"key":"4399_CR43","doi-asserted-by":"publisher","unstructured":"Murali S, Vogrin S, Noaman S, Dinh DT, Brennan AL, Lefkovits J, et al. Bleeding severity in percutaneous coronary intervention (PCI) and its impact on short-term clinical outcomes. J Clin Med. 2020;9. https:\/\/doi.org\/10.3390\/jcm9051426.","DOI":"10.3390\/jcm9051426"},{"key":"4399_CR44","doi-asserted-by":"publisher","unstructured":"Ng AK, Ng PY, Ip A, Lam LT, Siu CW. Trade-off of major bleeding versus myocardial infarction on mortality after percutaneous coronary intervention. Open Heart. 2022;9. https:\/\/doi.org\/10.1136\/openhrt-2021-001861.","DOI":"10.1136\/openhrt-2021-001861"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04399-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-024-04399-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04399-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T06:05:17Z","timestamp":1734588317000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-024-04399-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4399"],"URL":"https:\/\/doi.org\/10.1186\/s12872-024-04399-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3670350\/v1","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"27 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed according to the declaration of Helsinki. The study was approved by the Ethics Committee of the General Hospital of Northern Theater Command (ethical code: Y 2022-No.320). As a retrospective study, the need for informed consent was waived, and it has also been approved by the Ethics Committee of the General Hospital of Northern Theater Command.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"713"}}